Bronchiectasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Bronchiectasis is a chronic pulmonary ailment marked by persistent and enduring dilation of the bronchial airways and a weakening of the mucociliary transport mechanism, attributable to recurrent infections that facilitate bacterial invasion and mucus accumulation throughout the bronchial tree. Traditionally, antecedent respiratory infections, particularly in childhood, were considered the primary etiological factor. The causative factors encompass idiopathic, acquired, or infection-related origins. A predominant manifestation is an enduring cough with expectoration, characterized by a mixture of saliva and mucus expelled from the airways. Additional symptoms may encompass sinusitis, fatigue, dyspnea, wheezing, chest pain, and hemoptysis. Three pivotal mechanisms underlie the pathogenesis of bronchiectasis: recurrent infections, airway obstruction, and peribronchial fibrosis. Neutrophils assume a central role in airway inflammation, prompted by elevated concentrations of neutrophil chemoattractants such as interleukin-8 (CXCL-8) and leukotriene B4. Impaired mucociliary clearance and deficient neutrophil opsonophagocytic killing contribute to airway bacterial colonization. Immune dysfunction extends to the impaired clearance of apoptotic cells and T-cell invasion, with emerging evidence implicating Th17 cells. Histological alterations involve:

·       Cartilage destruction

·       Fibrosis

·       Mucosal and mucous gland hyperplasia

·       Inflammatory cell infiltration

·       Augmented mucous and exudate production

·       The disease exhibits a progressive course in conjunction with ciliary dysfunction and cystic fibrosis, potentially leading to respiratory failure. The prognosis is relatively favorable with regular postural drainage and judicious antibiotic use.

·       The prevalence of bronchiectasis rises with age, with a prevalence 8 to 10 times higher in individuals over 60 years (300 to 500 per 100,000) compared to those under 40 to 50 years (40 to 50 per 100,000).

 

Thelansis’s “Bronchiectasis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bronchiectasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Bronchiectasis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Bronchiectasis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Bronchiectasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Bronchiectasis, Bronchiectasis market outlook, Bronchiectasis competitive landscape, Bronchiectasis market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)